Platelet factor 3 effectiveness assay

Determination of the effectiveness of platelet factor 3, also known as platelet coagulation activity. Platelet factor 3 is a specific protein synthesized from platelet alpha particles and is a tetramer of a polypeptide. It easily binds and neutralizes heparin and easily binds to heparan sulfate on the surface of vascular endothelial cells to slow down the inactivation of thrombin and promote thrombosis. It is one of the phospholipid components of the platelet membrane and is an important factor for platelets to participate in the blood coagulation process. Its effectiveness declines, leading to coagulopathy. Basic Information Specialist classification: cardiovascular examination classification: blood examination Applicable gender: whether men and women apply fasting: fasting Tips: The use of antiplatelet drugs, such as dipyridamole, dextran, aspirin, phenylbutazone, etc., can prolong the clotting time. Therefore, these drugs should be stopped 1 week before the experiment. Normal value The clotting time of the recalcification method using white clay is not more than 5 seconds. Platelet factor IV normal value: plasma β-TG25.3±3.0μg/L, PF43.2±0.8μg/L. Clinical significance Prolonged: seen in congenital factor 3 deficiency, giant platelet syndrome, thrombocytopenia, cirrhosis, uremia, myeloproliferative disorders, multiple myeloma, megalinemia, aplastic anemia, congenital anemia abnormal protein Blood, thrombocytopenia, drug effects, etc. Increased plasma levels of β-TG and PF4 indicate that platelets are activated and their release response is hyperactive. Found in hypercoagulable state and/or thromboembolic diseases, such as acute myocardial infarction, cerebrovascular disease, uremia, pregnancy-induced hypertension syndrome, nephrotic syndrome, diabetic vasculopathy, disseminated intravascular coagulation, vascular sclerosis, Venous thrombosis. Therefore, β-TG measurement of ischemic heart and cerebrovascular disease prediction, the identification of diabetes with or without vascular disease, the importance of observing the prognosis of uremia. Precautions 1, the application of antiplatelet drugs, such as dipyridamole, dextran, aspirin, phenylbutazone, etc., can prolong the clotting time. Therefore, these drugs should be stopped 1 week before the experiment. 2, oral contraceptives, late pregnancy, high-fat diet and smoking, etc., can shorten the clotting time. Inspection process (1) 2.7 ml of blood was collected by a silicon or plastic syringe, and a silicon or plastic test tube containing 0.109 mol/L sodium citrate anticoagulant 0.3 ml was injected and mixed. The patient and the healthy person simultaneously took one blood each. (2) Anticoagulant sodium citrate was centrifuged at 1000 r/min for 10 min, and the supernatant was taken out as PRP; the remaining disturbed coagulation was centrifuged at 3000 r/min for 15 min, and the supernatant was taken out as PPP. (3) Four small test tubes were divided into 4 groups, and each tube was added with 0.1 ml of PRP and PPP. Not suitable for the crowd 1. Patients who have taken contraceptives, thyroid hormones, steroid hormones, etc., may affect the results of the examination and prohibit patients who have recently taken the drug history. 2, special diseases: patients with hematopoietic function to reduce disease, such as leukemia, various anemia, myelodysplastic syndrome, etc., unless the examination is essential, try to draw less blood. Adverse reactions and risks 1, subcutaneous hemorrhage: due to pressing time less than 5 minutes or blood draw technology is not enough, etc. can cause subcutaneous bleeding. 2, discomfort: the puncture site may appear pain, swelling, tenderness, subcutaneous ecchymosis visible to the naked eye. 3, dizzy or fainting: in the blood draw, due to emotional overstress, fear, reflex caused by vagus nerve excitement, blood pressure decreased, etc. caused by insufficient blood supply to the brain caused by fainting or dizziness. 4. Risk of infection: If you use an unclean needle, you may be at risk of infection.